Arsani William - 31 Aug 2021 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DSGN	Common Stock	Purchase	$618K	+40K	+1.46%	$15.45^*	2.77M	31 Aug 2021	By Logos Global Master Fund LP	F2, F3
holding	DSGN	Common Stock						1.22M	31 Aug 2021	By Logos Opportunities Fund II, L.P.	F1
holding	DSGN	Common Stock						2.03M	31 Aug 2021	By Logos SPV 1 LP	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2	The weighted average purchase price for the transaction was $15.45. The shares were purchased at a range of prices between $15.00 and $15.69, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F3	Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.